Montana- For the millionth time...stipulated facts state generic composition is the same as Vascepa composition. The current case does not involve valid non argued Amarin composition patents. These patents are enough for Amarin to seek an order to bar launch of the composition in any indication. It would be a separate legal action, but it is a valid Amarin move to stop infringement of IP. Hence patent 101 comment. It doesn’t matter about OB’d or not OB’d...this is outside FDA regulations and is just CFR.
Market Data 
Markets 
AI
